MiNK Therapeutics' AgenT-797 Achieves Complete Remission in Testicular Cancer Patient, Shares Soar

MiNK Therapeutics' (INKT) investigational cell therapy, AgenT-797, has rendered a testicular cancer patient disease-free, with the patient remaining cancer-free for over two years. The case highlights the potential of the off-the-shelf iNKT platform in treating solid tumors refractory to standard treatments and immunotherapy. INKT's stock has soared 175% in premarket trading. The company has a cash balance of $3.2 million and is currently enrolling participants in a phase II gastric cancer trial.

Title: MiNK Therapeutics Achieves Significant Milestone in Testicular Cancer Treatment

MiNK Therapeutics (INKT) has announced a groundbreaking case in Nature's Oncogene detailing a complete remission in a patient with metastatic testicular cancer using their investigational cell therapy, AgenT-797. The patient, who had failed multiple treatments including platinum-based chemotherapy and immunotherapies, achieved a complete remission lasting over two years after a single infusion of AgenT-797 combined with nivolumab.

The therapy demonstrated remarkable safety with no cytokine release syndrome or graft-versus-host disease, addressing two major concerns with cell therapies. This case adds to MiNK's growing clinical evidence portfolio, including their Phase 2 gastric cancer data showing extended survival beyond 12 months in several patients. The persistence of donor cells for six months post-infusion may explain the durability of response, suggesting these cells effectively reshape the tumor microenvironment to overcome prior treatment resistance.

While a single case cannot establish efficacy across broader populations, this complete remission in such a challenging context provides compelling rationale for expanded clinical development of iNKT cell therapies in solid tumors where treatment options remain limited. MiNK's stock has soared 175% in premarket trading, reflecting investor confidence in the company's innovative approach.

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies. The company's lead candidate, AgenT-797, is currently in clinical development for graft-versus-host disease (GvHD), solid tumors, and severe pulmonary inflammation. With a cash balance of $3.2 million, MiNK is currently enrolling participants in a Phase II gastric cancer trial.

References:
1. [MiNK Therapeutics Announces Publication of Complete Remission in Metastatic Testicular Cancer](https://www.stocktitan.net/news/INKT/mi-nk-therapeutics-announces-publication-of-complete-remission-5j2mmi5lt1nx.html)
2. [MiNK Therapeutics Inc. Announces Publication of Complete Remission Following Allogeneic iNKT-Cell Therapy](https://www.marketscreener.com/quote/stock/MINK-THERAPEUTICS-INC-128249930/news/MiNK-Therapeutics-Inc-Announces-Publication-of-Complete-Remission-Following-Allogeneic-iNKT-Cell-T-50490185/)